Vice | Jotup

OpsLab Announces Addition of Strategic Advisors, Including a Former Vice Chief of Staff of the U.S. Air Force

Retrieved on:

星期四, 五月 9, 2024

Air force, Investment, Weather, Policy, Machine learning, Vice, Research, Air Staff, Knowledge, Boeing, The, Assistant, Joint Chiefs of Staff, Atmosphere, Pentagon, Aviation, Management

AUSTIN, Texas, May 9, 2024 /PRNewswire-PRWeb/ -- At OpsLab, our primary focus is delivering outstanding results for our customers. In defense, that means ensuring we have clear direction from commanders and an acute understanding of the values that underpin their leadership. In commercial aviation, it means the diligent pursuit of cutting-edge operations solutions that minimize overall cost without sacrificing safety. Today, we are announcing three outstanding leaders as strategic advisors:

Key Points:

Today, we are announcing three outstanding leaders as strategic advisors:
GENERAL (R) STEPHEN W. "SEVE" WILSON.
Gen. Wilson held numerous leadership positions in his time with the United States Air Force, most recently as Vice Chief of Staff.
As the second-highest ranking military commander in the Air Force, he presided over the Air Staff and served as a member of the Joint Chiefs of Staff Requirements Oversight Council and Deputy Advisory Working Group.
Maj. Gen. (R) Corcoran served as the Assistant Deputy Chief of Staff, Operations, Headquarters U.S. Air Force, the Pentagon, Arlington, Virginia.

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Retrieved on:

星期二, 五月 7, 2024

ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points:

The trial is expected to enroll 92 evaluable patients and is expected to complete enrollment in the third quarter of 2024.
The trial has completed enrollment into the second cohort and a data readout are expected in the third quarter of 2024.
First Quarter Ended March 31, 2024 Financial Results
General and administrative expenses decreased to $1.9 million for the three months ended March 31, 2024, from $2.2 million for the three months ended March 31, 2023.
Cash and cash equivalents totaled $18.3 million as of March 31, 2024, compared to $23.2 million as of December 31, 2023.

Methode Electronics Announces CEO Transition

Retrieved on:

星期二, 五月 7, 2024

Methode Electronics, EidosMedia, Vice, Growth, Spencer Stuart, Brunswick Corporation, AlixPartners, Electronics, LED, Management

CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, LED lighting system and power distribution applications, announced today that Kevin Nystrom, a partner and managing director at AlixPartners LLP, has been appointed interim CEO, effective immediately. The company has previously disclosed its ongoing engagement with AlixPartners for various consulting services, including cost reduction and financial advisory.

Key Points:

Methode's Board of Directors, with the assistance of executive search firm Spencer Stuart, has initiated a search to identify a permanent CEO.
The company’s former President and Chief Executive Officer, Donald W. Duda, remains a strategic consultant to Methode through January 2025 and will continue to provide support during the transition period.
Walter J. Aspatore, Chairman of the Methode Board, said, “The Board will work diligently to undertake a comprehensive and timely search to identify a permanent CEO.
Mr. Nystrom said, “I look forward to joining Methode and leveraging my experience to advance the initiatives already underway, including driving operational efficiencies across the business.”

Lazard Welcomes Michele Colocci as Vice Chairman, Investment Banking and Managing Director, Healthcare

Retrieved on:

星期四, 五月 9, 2024

Lazard, Inc. (NYSE: LAZ) today announced Michele Colocci is joining the firm on 3rd June 2024 as Vice Chairman, Investment Banking and Managing Director, Healthcare.

Key Points:

Lazard, Inc. (NYSE: LAZ) today announced Michele Colocci is joining the firm on 3rd June 2024 as Vice Chairman, Investment Banking and Managing Director, Healthcare.
Mr. Colocci is a globally recognized advisor with a particular focus on healthcare, having worked with biopharma clients across EMEA, the US, and Japan.
With three decades of investment banking expertise, he most recently served as Managing Director and Chairman of M&A at Morgan Stanley, where among other previous leadership roles, he also served as Global Co-Head of Healthcare Investment Banking and as Deputy Head of European Investment Banking.
He previously also held the role of Global Co-Head of Healthcare Investment Banking at JPMorgan.

Andrew Briggs Appointed Chairman of Farmers & Merchants Bancorp, Inc. and F&M Bank

Retrieved on:

星期五, 五月 3, 2024

Limberlost Swamp, Treasurer, Vice, Sauder Woodworking Company, Farmer, Retirement, F&M Bank, Sagamore, Bank, Ball State University, Economic development, Ball, Management

ARCHBOLD, Ohio, May 03, 2024 (GLOBE NEWSWIRE) -- F&M Bank (“F&M”), an Archbold, Ohio-based bank owned by Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) announced the appointment of Andrew Briggs as Chairman of the Board of both the Company and the Bank.

Key Points:

ARCHBOLD, Ohio, May 03, 2024 (GLOBE NEWSWIRE) -- F&M Bank (“F&M”), an Archbold, Ohio-based bank owned by Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) announced the appointment of Andrew Briggs as Chairman of the Board of both the Company and the Bank.
Kevin Sauder, President and CEO of Sauder Woodworking Company, will continue to serve as Vice Chairman of the Boards of Farmers & Merchants Bancorp, Inc. and F&M Bank.
I wish him all the best on his retirement from F&M.”
Mr. Briggs, age 69, has served as a director of Farmers & Merchants Bancorp, Inc., and F&M Bank since 2019, and serves on the Enterprise Risk Management Board Committee.
He was the 2019 Chairman of the Indiana Bankers Associations and is a member of the Indiana Bankers 40 Year Club.

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Retrieved on:

星期二, 四月 23, 2024

Monitoring, Cancer, Patient, Inflammation, Safety, Radiation, SJD, The Study, Therapy, Vice, Eye, Sant Joan, Enucleation of the eye, Pharmaceutical industry

ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline data from the investigator sponsored Phase 1 trial conducted by collaborators at Sant Joan de Déu-Barcelona Children’s Hospital (SJD). The Phase 1 trial was designed to evaluate the safety and tolerability of two intravitreal injections of Theriva’s investigational oncolytic adenovirus VCN-01 in patients (n=9) with intraocular retinoblastoma that is refractory to chemotherapy or radiotherapy, and for whom enucleation was the only recommended treatment.

Key Points:

“Results from the investigator sponsored trial further validate VCN-01’s unique mechanism of action and therapeutic potential to improve patient outcomes in otherwise refractory cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
“We look forward to building on the encouraging safety profile and antitumor activity, which further supports and informs the design of our proposed Phase 2 clinical trial.
The Monitoring Committee determined that the trial results were positive, and therefore, Theriva will receive an exclusive, worldwide license, and related patents from SJD for the treatment of pediatric patients with advanced retinoblastoma.
Eye enucleation was avoided in 3 patients to date, one of whom has retained their eye after 4 years of follow-up.

Flexion awarded contract to revolutionize Head Start’s Data Management System

Retrieved on:

星期五, 四月 19, 2024

Health, Head Start, OHS, Vice, Risk management

MADISON, Wis., April 19, 2024 (GLOBE NEWSWIRE) -- Flexion is proud to announce that it has secured a significant contract to operate, maintain, and enhance the Head Start Enterprise System (HSES) for the Office of Head Start (OHS).

Key Points:

MADISON, Wis., April 19, 2024 (GLOBE NEWSWIRE) -- Flexion is proud to announce that it has secured a significant contract to operate, maintain, and enhance the Head Start Enterprise System (HSES) for the Office of Head Start (OHS).
This contract not only marks a major milestone for Flexion but also underscores our commitment to delivering innovative solutions that have the potential to revolutionize people's lives.
This ambitious project is set to transform HSES, the agency's primary data management system.
Flexion is committed to partnering with HSES to revitalize its legacy data management infrastructure.

Intrepid Announces Medical Leave of Absence for Bob Jornayvaz; Intrepid Co-founder Hugh Harvey rejoins Board of Directors

Retrieved on:

星期三, 四月 17, 2024

CO, Intrepid, CFO, Executive, Senior, Financial analyst, Intrepid Potash, Vice, Retirement, Family, IPI, Management

Denver, CO, April 17, 2024 (GLOBE NEWSWIRE) -- Intrepid Potash, Inc. ("Intrepid,” “we," or "our") (NYSE:IPI) today announced that on April 16, 2024, the Board of Directors (the “Board”) of Intrepid granted Bob Jornayvaz, Executive Chairman of the Board and Chief Executive Officer, a temporary medical leave of absence, effective immediately, as he recovers from his previously announced injury.

Key Points:

Denver, CO, April 17, 2024 (GLOBE NEWSWIRE) -- Intrepid Potash, Inc. ("Intrepid,” “we," or "our") (NYSE:IPI) today announced that on April 16, 2024, the Board of Directors (the “Board”) of Intrepid granted Bob Jornayvaz, Executive Chairman of the Board and Chief Executive Officer, a temporary medical leave of absence, effective immediately, as he recovers from his previously announced injury.
In connection with Mr. Jornayvaz’s leave of absence, the Board has appointed Matt Preston, Intrepid’s current Chief Financial Officer, as acting principal executive officer and announced that Intrepid’s co-founder, Hugh Harvey, has been appointed as a Class III Director.
The Board has also temporarily delegated all responsibilities of the Chairman of the Board to Barth Whitham, Intrepid’s Lead Director.
Matt Preston has been with Intrepid since 2008 and has served as our Chief Financial Officer (“CFO”) since December 2021 and principal financial officer since November 2019.

Macy's Honors Historically Black-Founded Fraternities of The Divine Nine® With Exclusive New Collection

Retrieved on:

星期三, 五月 1, 2024

In recognition and celebration of the legacy and impact of the five historically Black-founded fraternities of the National Pan-Hellenic Council (NPHC) known as The Divine Nine®, Macy’s has developed an exclusive and versatile product collection.

Key Points:

In recognition and celebration of the legacy and impact of the five historically Black-founded fraternities of the National Pan-Hellenic Council (NPHC) known as The Divine Nine®, Macy’s has developed an exclusive and versatile product collection.
With prices starting at $49, product will be exclusively available online at macys.com and in-store at select locations, with all pieces available by July 2024.
This new menswear collection compliments the Sorority collection, which launched in 2022 with The Kasper Group offering customers an evolving product assortment for signature events and conferences.
The assortment was created in partnership with Tayion Collection®, founded and designed by Montee Holland, a graduate of The Workshop at Macy’s and S.P.U.R.

Steve Jurvetson, a Renowned Silicon Valley Investor, Joins TMC’s Board of Directors as Vice Chairman and Special Advisor to the CEO

Retrieved on:

星期三, 四月 10, 2024

Copper, Skype, SpaceX, Nuclear fusion, TMC, Investment, AI, Innovation system, Planet Labs, Vice, Collection, Manganese, Cobalt, Commonwealth Fusion Systems, Initial public offering, Growth, Nickel, Renewable energy

For over 25 years, Mr. Jurvetson has been known for his early-stage venture investments in some of the world’s most impactful technology companies.

Key Points:

For over 25 years, Mr. Jurvetson has been known for his early-stage venture investments in some of the world’s most impactful technology companies.
Gerard Barron, Chairman and CEO of TMC, stated: “Steve Jurvetson is not just a legendary investor but a visionary with wide and deep-ranging curiosity.
With the increasing volume of scientific data at our disposal, it is imperative that we elevate the discourse on deep-seafloor metals.
I look forward to working with TMC to execute its forward-looking mission and maximize value to shareholders and stakeholders.”